Veterinary patients, including dogs and cats, can experience persistent pain similar to that experienced in humans, with a subsequent impact (sometimes severe) on quality of life. Such pain is often, but not always, associated with chronic inflammation and will often carry maladaptive and neuropathic components that increase the challenge of maximizing therapeutic plans. Furthermore, the duration of treatment can become a concern, as pain- and disease-modifying medications may need to be administeredfor extended periods of time, if notfor the remainder of the animal's life. It is therefore imperative to know (andprevent or manage) the potentialfor adverse drug events (ADE) that may accompany the long-term use of specific pharmacologic agents. The present review will describe the latest scientific evidence regarding pharmacokinetics, efficacy and tolerability of the main classes of those drugs potentially useful in the treatment of persistent pain, including non-steroidal anti-inflammatory drugs, acetaminophen, opioids and opioid-like drugs, gabapentinoids, NMDA-antagonists, serotonin and adrenaline reuptake inhibitors and palmitoylethanolamide.
Gestione farmacologica del dolore a lungo termine nel cane e nel gatto
DELLA ROCCA, Giorgia
2016
Abstract
Veterinary patients, including dogs and cats, can experience persistent pain similar to that experienced in humans, with a subsequent impact (sometimes severe) on quality of life. Such pain is often, but not always, associated with chronic inflammation and will often carry maladaptive and neuropathic components that increase the challenge of maximizing therapeutic plans. Furthermore, the duration of treatment can become a concern, as pain- and disease-modifying medications may need to be administeredfor extended periods of time, if notfor the remainder of the animal's life. It is therefore imperative to know (andprevent or manage) the potentialfor adverse drug events (ADE) that may accompany the long-term use of specific pharmacologic agents. The present review will describe the latest scientific evidence regarding pharmacokinetics, efficacy and tolerability of the main classes of those drugs potentially useful in the treatment of persistent pain, including non-steroidal anti-inflammatory drugs, acetaminophen, opioids and opioid-like drugs, gabapentinoids, NMDA-antagonists, serotonin and adrenaline reuptake inhibitors and palmitoylethanolamide.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
